Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-Term Follow-up of Subjects Who Were Treated With ST-920
Sponsor: Sangamo Therapeutics
Summary
Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.
Official title: Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
48
Start Date
2021-08-16
Completion Date
2039-03
Last Updated
2025-05-25
Healthy Volunteers
No
Interventions
ST-920
No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
Locations (13)
University of California, Irvine
Irvine, California, United States
University of South Florida
Tampa, Florida, United States
Emory University School of Medicine
Atlanta, Georgia, United States
University of Iowa Hospital and Clinics
Iowa City, Iowa, United States
University of Minnesota Medical Center
Minneapolis, Minnesota, United States
Mt. Sinai Hospital
New York, New York, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)
Fairfax, Virginia, United States
The Royal Melbourne Hospital
Parkville, Victoria, Australia
M.A.G.I.C. Clinic Ltd.
Calgary, Alberta, Canada
University Hospital of Würzburg
Würzburg, Germany
Addenbrooke's Hospital
Cambridge, United Kingdom
Royal Free Hospital
London, United Kingdom